http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2018199048-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-09 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-708 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6558 |
| filingDate | 2018-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2018199048-A1 |
| titleOfInvention | 5'-position monophosphoric acid dibenzyl ester derivative of nucleoside anticancer agent or antiviral agent |
| abstract | PROBLEM TO BE SOLVED: To have high stability against various hydrolytic metabolic enzymes in place of injections (nucleoside anticancer agents or antiviral agents) clinically used as therapeutic agents for cancer or viral infections. In addition, a drug that is absorbed into the body even by oral administration, is incorporated into the biosynthetic route of DNA and RNA, inhibits modification and elongation of DNA and RNA, inhibits reverse transcriptase, and inhibits protein synthesis, and exhibits a cell killing action. To provide. [Solution] Formula (I): (In the formula, D is a 5′-position of a nucleoside anticancer agent or antiviral agent, and R 1 and R 2 are the same or different benzyl groups each optionally having a substituent.) The novel compound represented by solves the above problems. [Selection diagram] None |
| priorityDate | 2017-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 641.